A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/S
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2024-511599-33-00
- Lead Sponsor
- oxo Oncology Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 282
Age 18 years or older per local regulations at time of enrollment. Type of Patient and Disease Characteristics, Confirmed diagnosis by redacted local laboratory report of CLL/SLL as defined by iwCLL 2018 criteria including the following: a) B-cells co-express CD5 and CD23; express at least one B-cell antigen (CD19 or CD20) and be either ? or ? light-chain restricted. Atypical cases may be considered with Sponsor approval. b) = 5 × 109 B lymphocytes/L (5000/µL) in the peripheral blood for CLL patients. For SLL patients, <5 × 109 B cells/L (5000/µL) in the peripheral blood is allowed. c) Prolymphocytes may comprise = 55% of blood lymphocytes (for CLL patients)., A requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy such that at least 1 of the following should be met: a) Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (such as hemoglobin < 10 g/dL) and/or thrombocytopenia (such as platelets = 100 × 109/L). b) Massive (i.e., spleen edge = 6 cm below the left costal margin) or progressive or symptomatic splenomegaly (> 13 cm). c) Massive nodes (i.e., = 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy. d) Progressive lymphocytosis with an increase of > 50% over a 2-month period, or lymphocyte doubling time < 6 months. Factors contributing to lymphocytosis other than CLL/SLL (e.g., infections, steroid administration) should be excluded. e) Autoimmune complications including anemia or thrombocytopenia poorly responsive to corticosteroids. f) Symptomatic or functional extranodal involvement (e.g., skin, kidney, lung, spine). g) Disease-related symptoms (also known as B-symptoms) as defined by any of the following: i) Unintentional weight loss = 10% within the previous 6 months. ii) Significant fatigue (i.e., Eastern Cooperative Oncology Group [ECOG] performance scale 2 or worse; cannot work or unable to perform usual activities). iii) Fevers = 100.5°F or 38.0°C for 2 or more weeks without evidence of infection. iv) Night sweats for = 1 month without evidence of infection., Eastern Cooperative Oncology Group (ECOG) 0-2., Must have adequate organ function, as defined below. Results from the most recent laboratory tests prior to enrollment will be used for eligibility., Patients are required the have had the following washout periods prior to planned C1D1: a) Palliative limited field radiation: 7 days b) Broad field radiation (= 30% of bone marrow or whole brain radiotherapy): 28 days Contraception, Willingness women of childbearing potential (WOCBP), and their partners, to both observe barrier method and highly effective birth control methods as outlined in Section 10.2 (Appendix 2; and below) for the duration of treatment and for 1 month following the last dose of pirtobrutinib or 12 months after the last dose of rituximab, whichever is later. WOCBP are defined as women following menarche, and who are not postmenopausal (or 2 years of non-therapy-induced amenorrhea, or surgically sterile). WOCBP must utilize 2 effective contraception methods with at least 1 form of highly effective contraception method as outlined below. In addition, male partners must use a barrier method (condoms) for the duration of treatment and for 1 month following the last dose of study treatment or 12 months after the last dose of rituximab. Male patients enrolled in Arm B with partners who are WOCBP must use a barrier method (condoms) and their partner must also
Known or suspected Richter's transformation to diffuse large B-cell lymphoma (DLBCL), prolymphocytic leukemia, or Hodgkin lymphoma at any time preceding enrollment., Hepatitis B or hepatitis C testing indicating active/ongoing infection based on Screening laboratory tests as defined as: a) Hepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require hepatitis B Polymerase chain reaction (PCR) evaluation before randomization. Patients who are hepatitis B PCR positive will be excluded. b) Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before randomization. Patients who are hepatitis C RNA positive will be excluded. c) For optional crossover, repeat testing is not required., Active cytomegalovirus (CMV) infection., Evidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal) or other clinically significant active disease process which in the opinion of the Investigator and Medical Monitor may pose a risk for patient participation. Screening for chronic conditions is not required., Known Human Immunodeficiency Virus (HIV) infection, regardless of CD4 count. Patients with unknown or negative status are eligible., Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the oral administered study treatments. Please refer to Protocol., Presence of 17p deletion by fluorescence in-situ hybridization (FISH) (refer to Section 8.10.2), Known or suspected history of central nervous system (CNS) involvement by CLL/SLL., Active second malignancy. Patients with treated second malignancy who are in remission with life expectancy > 2 years and with documented Sponsor approval are eligible. Examples include: a) Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease. b) Adequately treated cervical carcinoma in situ without current evidence of disease. c) Localized (e.g., lymph node negative) breast cancer treated with curative intent with no evidence of active disease present for more than 3 years and receiving adjuvant hormonal therapy. d) Localized prostate cancer undergoing active surveillance. e) History of treated and cured Hodgkin's disease or NHL within 5 years from diagnosis., Major surgery, within 4 weeks of planned start of study treatment., A significant history of renal, neurologic, psychiatric, endocrine, metabolic or immunologic, that, in the opinion of the Investigator, would adversely affect the patient's participation in this study or interpretation of study outcomes., Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) not on a stable regimen and dose for at least 4 weeks prior to study enrollment, Significant cardiovascular disease defined as any of the following: a) Unstable angina or acute coronary syndrome within the past 2 months, b) History of myocardial infarction within 3 months prior to planned start of study drug, c) Documented LVEF by any method of = 40% d) = Grade 3 NYHA functional classification system of heart failure, uncontrolled or symptomatic arrhythmias, Pr
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method